Karyopharm Therapeutics Inc (NASDAQ:KPTI) - Share price


Stock Report

Karyopharm Therapeutics Inc KPTI

Last Price
$4.73

Day Change
0.22|4.88%

As of 01/07/2022
16:30:56 EDT | USD
Minimum 15 Minutes Delay.

Last Close4.51
Day Range4.44 - 4.75
Mkt Cap375.60Mil
52-Wk Range4.02 - 14.73
Yield %-
ISINUS48576U1060
Volume1,519,802
P/E-
P/S1.53
P/CF-3.17

Share Price

Financials
201920202021
More ...
Income Statement
Revenue40.89108.09209.82
Operating Income-189.28-171.85-98.27
Net Income-199.59-196.27-124.09
Basic EPS-3.22-2.72-1.65
Avg. Diluted Shares Outstanding627275
Balance Sheet
Current Assets278.57276.53275.61
Non Current Assets16.3936.5229.70
Total Assets294.96313.05305.31
Current Liabilities46.3560.2073.72
Total Liabilities---
Total Equity49.7750.55-79.67
Cash Flow
Operating Cash Flow-190.82-160.23-107.12
Capital Expenditure-0.21-0.15-5.71
Free Cash Flow-191.03-160.38-112.83

In millions, except "Basic EPS". Currency is USD.

Company Profile

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's lead compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Growth

Fiscal Year Ends

December

Employees

442
Key Stats
More ...
Price/Earning TTM-3.20
Price/Book-4.31
Price/Sales TTM1.62
Rev Growth (3 year avg)90.53
EPS Growth (3 year avg)-
Operating Margin % TTM-46.84
Net Margin % TTM-59.14
ROE TTM-
Debt/Equity-
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.